Vir Biotechnology, Inc. (VIR), a prominent immunology company, announced on Wednesday that Dr. Mark Eisner will join the company as Executive Vice President and Chief Medical Officer (CMO), effective June 3, 2024.
In his new role, Dr. Eisner will be part of the Executive Management Team and will report directly to Chief Executive Officer Marianne De Backer.
Dr. Eisner brings extensive expertise in immunology and infectious diseases, backed by significant clinical development experience. He has a proven track record of successfully leading teams during periods of strategic portfolio evolution.
Prior to joining Vir Biotechnology, Dr. Eisner served as CMO at Sonoma Biotherapeutics. Before his tenure at Sonoma, he was the CMO at FibroGen, where he oversaw all development functions, including the role of Head of China Clinical Development and Clinical Operations.
Dr. Eisner also spent nearly 11 years at Genentech, where he held the position of Senior Vice President and Global Head of Product Development for Immunology, Infectious Diseases, and Ophthalmology.
